Renal physiology

Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection

Retrieved on: 
Monday, January 7, 2019
Medicine, Creatinine, Guanidines, Metabolism, Renal physiology, Health, Organ transplantation, Transplant rejection, Kidney, Clinical Laboratory Improvement Amendments

The 13 cases are considered "subclinical AR," because the patients otherwise had stable renal function based on serum creatinine, showing no clinical signs of rejection.

Key Points: 
  • The 13 cases are considered "subclinical AR," because the patients otherwise had stable renal function based on serum creatinine, showing no clinical signs of rejection.
  • In the study, Natera's assay detected the subclinical AR cases with 92% sensitivity and 75% specificity.
  • Natera's organ transplant rejection assay is designed to detect active allograft rejection in patients who have undergone renal (kidney) transplantation.
  • Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif.

FDA Grants Breakthrough Device Status for MediBeacon's Transdermal GFR Measurement System

Retrieved on: 
Monday, October 22, 2018
Renal physiology, Anatomy, Renal function, Kidney, HC2 Holdings, Medicine, Kidney diseases, Physiology, Nephrology

ST. LOUIS, Oct. 22, 2018 /PRNewswire/ -- MediBeacon Inc ., whose largest shareholder is Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC), announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the company's Transdermal GFR Measurement System (TGFR).

Key Points: 
  • ST. LOUIS, Oct. 22, 2018 /PRNewswire/ -- MediBeacon Inc ., whose largest shareholder is Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC), announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the company's Transdermal GFR Measurement System (TGFR).
  • The ability to measure GFR is of high clinical interest especially in patients with or at risk of kidney disease.
  • "We are extremely excited about MediBeacon's breakthrough real-time kidney function measurement system," said Philip Falcone, HC2's Chairman, Chief Executive Officer and President.
  • This system, currently in human trials, is designed to enable clinically practical point of care measurement of a patient's kidney function.

The global creatinine measurement market projected to grow at a CAGR of 8.4%

Retrieved on: 
Thursday, June 28, 2018
Renal physiology, Creatinine, Guanidines, Metabolism, Compound annual growth rate

The global creatinine measurement market is expected to reach USD 564.5 million by 2023 from USD 377.2 million in 2018, at a CAGR of 8.4%.

Key Points: 
  • The global creatinine measurement market is expected to reach USD 564.5 million by 2023 from USD 377.2 million in 2018, at a CAGR of 8.4%.
  • Enzymatic method is expected to grow at the highest CAGR during the forecast period.
  • Based on type of sample the creatinine measurement market is segmented into blood/serum and urine samples.The blood/serum segment is expected to hold the largest share of the market and is also projected to grow at the highest CAGR during the forecast period.
  • On the basis of end user, the creatinine measurement market is segmented into hospitals and diagnostic laboratories.In 2018, the hospitals segment is expected to account for the largest share of the creatinine measurement market.

Global Creatinine Measurement 2018-2023: Commercialization of Advanced Testing Methods Presents Market Opportunities

Retrieved on: 
Friday, June 15, 2018
Guanidines, Chemistry, Renal physiology, Creatinine, Metabolism, Biology, Creatine

The "Creatinine Measurement Market by Product, Test Type, Sample and End User , Region - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Creatinine Measurement Market by Product, Test Type, Sample and End User , Region - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%.
  • This report segments the creatinine measurement market on the basis of type, type of sample, end user, product, and region.
  • In 2018, the Jaffe's kinetic method segment is estimated to account for the largest share of the creatinine measurement market, as it is the oldest and most conventional method for creatinine measurement in clinical samples.

Creatinine Measurement Market Worth 564.5 Million USD by 2023

Retrieved on: 
Monday, June 11, 2018
Renal physiology, Chemistry, Creatinine, Guanidines, Metabolism, Biology, Nephrology, Jaffe reaction, BUN-to-creatinine ratio

According to a new market research report "Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023", published by MarketsandMarkets, the global market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%.

Key Points: 
  • According to a new market research report "Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023", published by MarketsandMarkets, the global market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%.
  • The Creatinine Measurement Market, by test type, is segmented into the Jaffe's kinetic method and enzymatic method.
  • In 2018, the Jaffe's kinetic method segment is expected to hold the largest share of the Creatinine Measurement Market.
  • Most creatinine measurement kits and reagents are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration and low risk of contamination.